Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADIL NASDAQ:CWBR NASDAQ:ONCO NASDAQ:SNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADILAdial Pharmaceuticals$0.47+3.7%$0.48$0.22▼$3.00$4.88M1.023.04 million shs1.50 million shsCWBRCohBar$0.41$0.41$0.00▼$1.01$1.19M1.394,364 shsN/AONCOOnconetix$3.91+13.8%$5.42$3.16▼$656.88$2.07M3.38135,998 shs221,723 shsSNGXSoligenix$1.42+4.0%$1.64$1.09▼$6.17$4.61M1.87344,076 shs122,110 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADILAdial Pharmaceuticals0.00%+17.19%+83.86%-30.58%-58.61%CWBRCohBar0.00%0.00%0.00%0.00%+70.48%ONCOOnconetix0.00%-18.68%-17.90%-25.47%-99.40%SNGXSoligenix0.00%+7.09%-20.00%-34.30%-77.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADILAdial Pharmaceuticals2.1581 of 5 stars3.82.00.00.01.10.01.3CWBRCohBarN/AN/AN/AN/AN/AN/AN/AN/AONCOOnconetix0.2414 of 5 stars0.02.00.00.01.70.00.6SNGXSoligenix2.4558 of 5 stars3.53.00.00.01.80.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADILAdial Pharmaceuticals 3.50Strong Buy$8.001,609.40% UpsideCWBRCohBar 0.00N/AN/AN/AONCOOnconetix 0.00N/AN/AN/ASNGXSoligenix 3.00Buy$6.00324.03% UpsideCurrent Analyst Ratings BreakdownLatest CWBR, ADIL, SNGX, and ONCO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025SNGXSoligenixAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $6.00(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADILAdial PharmaceuticalsN/AN/AN/AN/A$0.64 per shareN/ACWBRCohBarN/AN/AN/AN/A$5.27 per shareN/AONCOOnconetix$2.52M0.82N/AN/A$11.22 per share0.35SNGXSoligenix$120K38.44N/AN/A$1.64 per share0.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADILAdial Pharmaceuticals-$13.20M-$1.46N/AN/AN/AN/A-218.88%-177.61%8/12/2025 (Estimated)CWBRCohBar-$12.18MN/A0.00∞N/AN/AN/AN/AN/AONCOOnconetix-$58.69MN/A0.00∞N/A-2,913.71%-514.04%-75.82%8/27/2025 (Estimated)SNGXSoligenix-$8.27M-$4.29N/AN/AN/AN/A-223.89%-103.50%8/8/2025 (Estimated)Latest CWBR, ADIL, SNGX, and ONCO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025N/AADILAdial Pharmaceuticals-$0.25N/AN/AN/AN/AN/A8/8/2025Q2 2025SNGXSoligenix-$0.79N/AN/AN/AN/AN/A6/12/2025Q1 2025ONCOOnconetixN/A$21.25N/A-$0.53N/A$0.10 million5/14/2025Q1 2025ADILAdial Pharmaceuticals-$0.50-$0.34+$0.16-$0.34N/AN/A5/9/2025Q1 2025SNGXSoligenix-$0.67-$1.06-$0.39-$1.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADILAdial PharmaceuticalsN/AN/AN/AN/AN/ACWBRCohBarN/AN/AN/AN/AN/AONCOOnconetixN/AN/AN/AN/AN/ASNGXSoligenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADILAdial PharmaceuticalsN/A1.991.99CWBRCohBarN/AN/AN/AONCOOnconetixN/A0.170.16SNGXSoligenixN/A1.851.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADILAdial Pharmaceuticals16.41%CWBRCohBar2.47%ONCOOnconetix23.89%SNGXSoligenix3.60%Insider OwnershipCompanyInsider OwnershipADILAdial Pharmaceuticals4.26%CWBRCohBar6.51%ONCOOnconetix3.10%SNGXSoligenix3.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADILAdial Pharmaceuticals2010.44 million9.99 millionNo DataCWBRCohBar102.91 millionN/ANot OptionableONCOOnconetix12530,000516,000N/ASNGXSoligenix203.26 million3.16 millionNot OptionableCWBR, ADIL, SNGX, and ONCO HeadlinesRecent News About These CompaniesAlliance Global Partners Cuts Soligenix (NASDAQ:SNGX) Price Target to $6.00July 19 at 4:19 AM | americanbankingnews.comSNGX: Multiple Catalysts Upcoming in 2H25…July 11, 2025 | finance.yahoo.comSoligenix Corporate Update Letter - Key Highlights and Upcoming MilestonesJuly 8, 2025 | prnewswire.comSoligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions - Seeking AlphaJuly 3, 2025 | seekingalpha.comSoligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma SolutionsJuly 1, 2025 | prnewswire.comSoligenix Approves 2025 Equity Incentive Plan at MeetingJune 20, 2025 | tipranks.comSoligenix (NASDAQ: SNGX) Makes Advancement in Proprietary Treatment for Behçet’s DiseaseJune 17, 2025 | theglobeandmail.comSoligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical TrialsJune 6, 2025 | finance.yahoo.comSoligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical TrialsJune 6, 2025 | globenewswire.comSoligenix’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results in Rare Cancer TrialMay 24, 2025 | theglobeandmail.comSoligenix (NASDAQ: SNGX) Reports Q1 Milestones, Financial ResultsMay 20, 2025 | theglobeandmail.comSNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte™ in CTCL…May 13, 2025 | finance.yahoo.comSOLIGENIX, INC.: Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial ResultsMay 9, 2025 | finanznachrichten.deSoligenix Announces Recent Accomplishments And First Quarter 2025 Financial ResultsMay 9, 2025 | prnewswire.comSoligenix (NASDAQ: SNGX) CEO Highlights Pipeline and Strategy in BioMedWire Podcast EpisodeMay 7, 2025 | theglobeandmail.comSoligenix (NASDAQ: SNGX) CEO Highlights Pipeline and Strategy in BioMedWire Podcast EpisodeMay 7, 2025 | theglobeandmail.comIBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Christopher Schaber, CEO of Soligenix Inc.May 7, 2025 | finance.yahoo.comSoligenix $SNGX HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA FundingApril 30, 2025 | msn.comSolgenix shares rise on positive skin cancer treatment resultsApril 24, 2025 | investing.comFireside Chat with Christopher Schaber, Chief Executive Officer of Soligenix, Inc.April 24, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCWBR, ADIL, SNGX, and ONCO Company DescriptionsAdial Pharmaceuticals NASDAQ:ADIL$0.47 +0.02 (+3.72%) As of 12:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.CohBar NASDAQ:CWBRCohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.Onconetix NASDAQ:ONCO$3.91 +0.47 (+13.75%) As of 12:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.Soligenix NASDAQ:SNGX$1.42 +0.06 (+4.04%) As of 12:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Q2 Could Be the Catalyst PayPal Investors Have Been Waiting For Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
